Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Imatinib Mesylate 60Cyclophosphamide 57fludarabine phosphate 51fludarabine 43Whole-Body Irradiation 41Mycophenolic Acid 41Tacrolimus 33nilotinib 31Dasatinib 31Busulfan 29Peripheral Blood Stem Cell Transplantation 23Cyclosporine 22Melphalan 21Thiotepa 20Granulocyte Colony-Stimulating Factor 19Filgrastim 18thymoglobulin 17Cytarabine 17Antilymphocyte Serum 15Stem Cell Transplantation 14sargramostim 13Methotrexate 13ponatinib 12asciminib 10Cyclosporins 10Cord Blood Stem Cell Transplantation 10bosutinib 9Rituximab 9Interferon-alpha 9Clofarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × troxacitabine × Clear all
NCT00012259 2021-06-10

Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

Takeda

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡